Search

Displaying results 5231 - 5240 of 10000 in total
  1. Drug

    Orticumab

    go.drugbank.com/drugs/DB16653
    Investigational

    Orticumab is under investigation in clinical trial NCT04776629 (A Proof-of-activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors).

  2. Drug

    Bentracimab

    go.drugbank.com/drugs/DB16659
    Investigational

    Bentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure).

    Categories: Heterocyclic Compounds, 2-Ring
  3. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    Endogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h. … episodes in patients with hemophilia A.

  4. Drug

    Oxelumab

    go.drugbank.com/drugs/DB16663
    Investigational

    Oxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).

  5. Drug

    Pimivalimab

    go.drugbank.com/drugs/DB16667
    Investigational

    Pimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After

  6. Drug

    Torudokimab

    go.drugbank.com/drugs/DB16671
    Investigational

    Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With Moderate-to-severe Atopic Dermatitis).

  7. Drug

    Uliledlimab

    go.drugbank.com/drugs/DB16675
    Investigational

    Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for Advanced Solid Tumor).

  8. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    [A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time. … Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.

    Categories: Heterocyclic Compounds, 1-RingSynonyms: K-CAB
  9. Drug

    Insulin icodec

    go.drugbank.com/drugs/DB16693
    ApprovedInvestigational

    [L50758,A263818] Insulin icodec was approved by Health Canada in March 2024 for the treatment of adult patients with type 1 or 2 diabetes mellitus,[L50758] and was subsequently approved by the EMA in … It is a re-engineered version of the ultra long-acting oral basal insulin OI338, with several modifications introduced to significantly extend the half-life.

  10. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). … [A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5.

    Products: EMPAVELI® 54 MG/ML SOLUCIÓN INYECTABLE